Sathish Itikyala, MD
Rheumatology · West Plains, MONPI 1104267434
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $321 and has fallen 87.5% since, to $40 in 2024. That places this record below the midpoint for rheumatology clinicians in MO, where the typical reported total is $1,657.
Across 46 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$158
- Amgen$146
- Johnson & Johnson$113
- E.r. Squibb & Sons, L.L.C.$110
- Novartis$58
- Radius Health, Inc.$43
- plus $134 from 8 others
What the payments were for
- Food & beverage$72195%
- Education$405%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $158 |
| Amgen | 9 | $146 |
| Johnson & Johnson | 8 | $113 |
| E.r. Squibb & Sons, L.L.C. | 7 | $110 |
| Novartis | 3 | $58 |
| Radius Health, Inc. | 3 | $43 |
| Sanofi | 1 | $24 |
| AstraZeneca | 1 | $20 |
| Pfizer | 1 | $19 |
| GSK | 1 | $17 |
| Bristol Myers Squibb | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| UCB, Inc. | 1 | $12 |
How this compares
$761 in reported general payments places this provider in the 35th percentile of 134 rheumatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 135 | $989,333 |
| RinvoqUpadacitinib | 107 | $657,975 |
| EnbrelEtanercept | 73 | $513,544 |
| XeljanzTofacitinib Citrate | 79 | $493,618 |
| Xeljanz XrTofacitinib Citrate | 45 | $279,207 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 32 | $235,401 |
| HumiraAdalimumab | 30 | $233,012 |
| Humira(Cf) PenAdalimumab | 17 | $205,009 |
| Cosentyx SyringeSecukinumab | 12 | $203,105 |
| Cimzia (2 Pack)Certolizumab Pegol | 28 | $183,572 |
| Enbrel SureclickEtanercept | 27 | $177,072 |
| Orencia ClickjectAbatacept | 25 | $158,625 |
| OtezlaApremilast | 26 | $127,933 |
| Humira(Cf)Adalimumab | 12 | $81,739 |
| BenlystaBelimumab | 13 | $63,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira, Humira(Cf) | $158 | $972,726149 claims |
| AmgenEnbrel, Otezla | $146 | $641,47799 claims |
| PfizerXeljanz | $19 | $493,61879 claims |
| UCB, Inc.Cimzia (2 Pack) | $12 | $183,57228 claims |
| GSKBenlysta | $17 | $63,27713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 134 rheumatology providers in Missouri.
Other rheumatology in West Plains
- Melinda ReedWest Plains$11K
- Anne WinklerCarthage$1.6M
- Adam KilianSaint Louis$565K
- Alfred KimSaint Louis$486K
- Mark BoxKansas City$304K
- Sona KamatSaint Louis$268K
- Robert JacksonMemphis$152K
- Richard BrasingtonSaint Louis$100K
- Michael JosephJoplin$94K
- Ghaith NoaisehKansas City$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.